Recent Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide did not deliver cognitive benefits. Nevertheless, experts say these results mark an important shift in how researchers approach Alzheimer’s disease—moving away from single-target therapies toward addressing the condition as a network of complex, interrelated biological pathways, similar to the evolution seen in cancer treatment.
Limited Approved Options Highlight the Need for New Strategies
Currently, only two drugs—Kisunla from Eli Lilly and Leqembi from Eisai and Biogen—have been approved to slow Alzheimer’s progression. Both reduce toxic amyloid plaques in the brain and have shown around a 30% delay in disease progression. However, researchers increasingly acknowledge that targeting amyloid alone will not be sufficient to halt or reverse the disease.
Globally, more than 55 million people live with dementia, and Alzheimer’s accounts for about 60% of cases. The disease is defined by the buildup of amyloid and tau proteins, but scientists now recognise that multiple biological processes drive its progression.
Early Diagnosis and Patient Differences Matter
As reported by Reuters, experts stress that Alzheimer’s is not a uniform disease. Blood and genetic tests to identify biomarkers are becoming more accessible, although many patients still require spinal taps or costly PET scans. Studies suggest that treatment responses vary by factors such as sex, tau levels, genetic risk, and even race, with some patients likely needing combination therapies.
Importantly, evidence indicates that patients treated earlier in the disease course respond better than those with established cognitive impairment.
Learning from Oncology’s Transformation
Drawing parallels with cancer care, researchers note that oncology evolved from one-size-fits-all chemotherapy to personalised regimens targeting specific mutations and immune pathways. Alzheimer’s research is now following a similar path.
Scientists are developing drugs that target tau, address mixed or co-existing dementias, or act on multiple disease mechanisms simultaneously. Roche’s trontinemab, designed to cross the blood-brain barrier more effectively, and Annovis Bio’s multi-target drug buntanetap exemplify this next generation of therapies.
Toward Personalised, Combination Therapies
Experts agree that the future of Alzheimer’s treatment lies in tailored, combination approaches based on early diagnosis and precise biomarkers. Although setbacks remain common, researchers say the field is entering a promising new era focused on treating the full biological complexity of the disease rather than a single pathway.